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Abstract The serine/threonine kinase protein kinase B (PKB/
Akt) has been shown to play a crucial role in the control of
diverse and important cellular functions such as cell survival and
glycogen metabolism. There is also convincing evidence that
PKB plays a role in the insulin-mediated regulation of glucose
transport. Furthermore, states of cellular insulin resistance have
been shown to involve impaired PKB activation, and this usually
coincides with a loss of glucose transport activation. However,
evidence to the contrary is also available, and the role of PKB in
the control of glucose transport remains controversial. Here we
provide an overview of recent findings, discuss the potential
importance of PKB in the regulation of glucose transport and
metabolism, and comment on future directions. ß 2001 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
The cloning of the serine/threonine kinase protein kinase B
(PKB) also known as c-Akt (the cellular homologue of the
viral oncogene v-Akt) nearly 10 years ago heralded a new era
in our understanding of the propagation of hormonal and
survival signals in mammalian cells (for reviews see [1,2]).
PKB, a 57 kDa protein, was so named because of its high
homology with protein kinase A and protein kinase C (PKC),
and it is known to exist as three isoforms, K, L and Q (Akt1,
Akt2 and Akt3, respectively) [2]. Each isoform possesses an
amino-terminal pleckstrin homology (PH) domain, a kinase
domain and a carboxy-terminal regulatory domain [1]. PKB is
activated rapidly in response to insulin and growth factors in
a phosphoinositide 3-kinase (PI3K)-dependent fashion, in
what is believed to be a two step process. The ¢rst step in-
volves the stimulus-dependent production of 3-phosphoinosi-
tides (PtdIns(3,4)P2 and PtdIns(3,4,5)P3) by PI3K, which bind
to the PH domain of PKB and are thought to induce a con-
formational change in the kinase. The second step involves the
translocation of PKB from a mainly cytosolic localisation to
the plasma membrane, where the kinase is activated by phos-
phorylation [3]. The nature of the mechanism by which PKB
is recruited to the cell surface is far from clear, but recent
work from our laboratory indicates that an intact actin cyto-
skeleton, which permits the insulin-dependent production of
3-phosphoinositides, appears to be necessary [4]. The phos-
phorylation of PKB occurs at two speci¢c regulatory sites,
one localised in the kinase domain (Thr308 for PKBK) and
the other in the C-terminal regulatory domain (Ser473 for
PKBK) [1,2]. The kinase responsible for the phosphorylation
of the Thr308 site has been identi¢ed as a 3-phosphoinositide-
dependent kinase (PDK1) [5,6]. The identity of the kinase
responsible for phosphorylating the Ser473 site (putatively
termed PDK2) remains elusive, although integrin-linked ki-
nase [7], PDK1 [8], and PKB autophosphorylation [9] have
all been proposed as potential mediators of the phosphoryla-
tion of this second regulatory site.
The importance of PI3K in the propagation of multiple
signals including insulin and cell survival signals, led naturally
to an investigation of the role of PKB in these processes.
Numerous studies have demonstrated recently that PKB has
a key function in relaying the PI3K survival signal, and that it
acts as an anti-apoptotic signalling kinase in a variety of cell
types (for review see [10]). PKB has been shown to modulate
the activity of proteins mediating apoptosis, including the pro-
apoptotic factor, BAD, members of the forkhead family of
transcription factors, the nuclear factor CREB, the pro-apo-
ptotic protease caspase 9 and the transcription factor NF-UB
[10]. In addition to its involvement in regulating cell survival,
there is accumulating evidence to indicate that PKB is impor-
tant in mediating the e¡ects of insulin on glucose utilisation in
skeletal muscle and adipocytes, and this review will focus on
recent progress made in this area.
2. PKB ^ a regulator of glycogen synthesis and glucose
transport
Insulin promotes a variety of important biological responses, but
among the best documented is its ability to stimulate the disposal of
blood glucose, primarily in target tissues such as skeletal muscle and
adipocytes, where the sugar is either oxidised or stored as glycogen or
fatty acids. In both tissues insulin promotes a rapid activation of
speci¢c PKB isoforms. PKBK is the major isoform expressed in skel-
etal muscle, whereas PKBL is the predominant subtype in adipocytes
[11]. Although PKBQ is not activated to any signi¢cant extent in
skeletal muscle or adipocytes, its stimulation has been observed in
several cell lines [11]. One of the ¢rst physiological targets of PKB
to be identi¢ed was glycogen synthase kinase-3 (GSK3) [12], which
has been implicated in the control of many cellular processes, includ-
ing glycogen and protein synthesis, and the modulation of transcrip-
tion factor activity [1]. In unstimulated cells, GSK3 is active and
contributes signi¢cantly towards the phosphorylation and inhibition
of glycogen synthase [12]. Insulin stimulates glycogen synthesis both
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by inactivating GSK3 and also by promoting the dephosphorylation
of glycogen synthase. The inactivation of GSK3K and GSK3L is
achieved through phosphorylation of Ser21 and Ser9, respectively
[12], and this is mediated by PKB in a PI3K-dependent fashion.
Thus PI3K, PDK, PKB and GSK3 constitute one important arm of
the insulin signalling cascade regulating glycogen synthesis.
Another important metabolic response to insulin is the stimulation
of glucose transport in skeletal muscle and adipocytes, which is largely
due to the translocation of the insulin-regulated glucose transporter,
GLUT4, from its intracellular storage pool to the plasma membrane
(for review see [13]). PI3K is a crucial intermediate in the insulin
signalling process that leads to the translocation of GLUT4 and the
associated stimulation of glucose transport [14]. As it became clear
that PKB activation was dependent on the production of 3-phospho-
inositides by PI3K [15], workers were quick to test the hypothesis that
PKB might play a role in the stimulation of glucose transport by
insulin. The potential involvement of PKB isoforms in the hormonal
regulation of glucose transport has been based largely on studies in-
volving over-expression of constitutively active mutants of PKB in
isolated rat adipocytes [16], 3T3-L1 adipocytes [17,18] and L6 muscle
cells [19,20]. In L6 cells expression of such mutants led to an increase
in the basal activity of PKB that was accompanied by a signi¢cant
stimulation in glucose uptake, to a level comparable to that elicited
normally by insulin in untransfected control cells. The observed in-
crease in glucose transport was primarily attributable to an increase in
the plasma membrane recruitment of GLUT4, but not that of the
GLUT1 transporter [18,19]. In addition to inducing an increase in
glucose transport, over-expression of PKB in L6 muscle cells elicited
an inhibition of GSK3 and a concomitant increase in glycogen and
protein synthesis [19,20]. Another recent study showed that microin-
jection of either a PKB substrate peptide or an antibody directed
against PKB into 3T3-L1 adipocytes could prevent, in part, the trans-
location of GLUT4 by insulin [21]. However, whilst these ¢ndings are
consistent with the idea that PKB plays a role in the hormonal acti-
vation of glucose transport, work from Kasuga’s group suggested
otherwise. Kitamura et al. [22] suppressed the hormonal activation
of the endogenous PKB in 3T3-L1 adipocytes by expressing a dom-
inant negative form of the kinase, in which both regulatory phosphor-
ylation sites (Thr308 and Ser473) had been mutated to an alanine. In
cells transfected with this double ‘AA’ mutant, the hormonal activa-
tion of PKB was suppressed byV80% [22]. The authors reported that
under such circumstances insulin failed to activate protein synthesis,
but was nevertheless able to stimulate GLUT4 translocation and glu-
cose transport [22]. The reason why this study is at odds with the
majority, which have implicated PKB in the regulation of glucose
transport, is unclear. However, our studies in L6 muscle cells over-
expressing wild-type PKB have indicated that the stimulation of glu-
cose transport requires only a very small activation of PKB (V3-
fold), whereas other cellular responses such as the inactivation of
GSK3 may require a greater stimulation in PKB activity [19]. Thus,
given that the activity of the endogenous PKB was not suppressed
completely by the over-expressed dominant negative mutant in the
study by Kitamura et al. [22], it is plausible that the residual endog-
enous activity was su⁄cient to elicit an increase in glucose transport.
More evidence supporting this view comes from the work of Wang et
al. [23], who assessed PKB involvement in the insulin-stimulated
translocation of GLUT4 in L6 myoblasts. These workers co-trans-
fected constructs expressing c-myc-tagged GLUT4 and an ‘AAA’
PKB mutant, which contained a replacement of both the regulatory
phosphorylation sites and of the Lys179 residue that participates in
ATP binding [3]. Muscle cells transfected with this mutant failed to
display any stimulation of the endogenous PKB and, furthermore,
failed to induce GLUT4 translocation in response to insulin [23].
An important issue that remains unresolved concerns the mecha-
nism by which PKB promotes GLUT4 translocation to the plasma
membrane in response to insulin. Studies in 3T3-L1 adipocytes sug-
gest that insulin induces the re-localisation of PI3K from the cytosol
to GLUT4-containing vesicles [24^26]. This observation implies that
targeting of PI3K to such vesicles may result in the localised produc-
tion of 3-phosphoinositides that may support the recruitment of PKB
to vesicles harbouring GLUT4. Indeed, studies in 3T3-L1 adipocytes
and rat cardiac ventricular muscle have shown that PKBL associates
with GLUT4 vesicles following insulin treatment [27,28]. It is thus
plausible that activated PKB phosphorylates speci¢c GLUT4
vesicle-associated proteins involved in the translocation of the trans-
porter to the plasma membrane. For such a scenario to operate there
may also be a requirement to localise PDK1/2 to such membranes.
However, whilst this scheme appears attractive, there is no evidence at
present to indicate that PDK1 co-localises with GLUT4 in its intra-
cellular storage compartment. Alternatively, PKB may be activated at
the plasma membrane by PDK1/2 in response to insulin and then re-
localise to GLUT4 vesicles, where it may promote their translocation
to the cell surface (Fig. 1).
3. Modulators of PKB signalling ^ consequences for glucose
metabolism and insulin sensitivity
An important caveat to interpretation of the above studies
involving either stable or transient expression of active or
dominant negative forms of PKB is the possibility that such
approaches may have unforeseen consequences for the expres-
sion and/or activity of proteins regulating glucose utilisation.
Thus the issue of whether PKB is truly an upstream compo-
nent in the signalling cascade initiating GLUT4 translocation
may only be resolved when selective cell permeable inhibitors
of PKB become available. Nevertheless, one would assume
that if PKB is a crucial insulin signalling intermediate regu-
lating glucose metabolism, then its impaired activation should
have important implications for the hormonal stimulation of
glucose transport. Indeed, there is mounting evidence to sup-
port this assumption, some of which is reviewed below.
3.1. Possible modulators of PKB activity during
insulin signalling
Recent work has provided evidence that atypical PKC has a
role to play in insulin signalling and glucose transport activa-
tion. PKCj/V is activated by insulin in a PI3K-dependent
manner in rat adipocytes [29], 3T3-L1 adipocytes [30] and
L6 muscle cells [31]. The use of PKCj inhibitors and inactive
mutants has demonstrated a requirement for this kinase for
full insulin stimulation of glucose transport. Moreover, insulin
induces the phosphorylation of PKCj by PDK1, and the re-
localisation of PKCj to GLUT4 vesicles in rat adipocytes
[32]. These studies indicate that there may be a requirement
for activation of both PKB and PKCj for GLUT4 transloca-
tion and subsequent glucose transport stimulation, but there is
also evidence that atypical PKC may regulate PKB activity
negatively in certain cells [33,34]. In any case, the precise role
of atypical PKC in regulating or potentiating PKB-directed
GLUT4 translocation is yet to be determined.
Since PKB activation is dependent upon the generation of
3-phosphoinositides including PtdIns(3,4,5)P3, a potential
mechanism for regulation of the kinase is via lipid phospha-
tases, and recent work from Olefsky’s group suggests that this
may in fact be the case. Vollenweider et al. investigated the
e¡ect of SH2-containing inositol phosphatase (SHIP) on in-
sulin signalling in 3T3-L1 adipocytes [35]. This study indicated
that SHIP, a 5-phosphatase, inhibited hormone-stimulated
GLUT4 translocation, and was also e¡ective in preventing
GLUT4 translocation induced by expression of a mem-
brane-targeted catalytic subunit of PI3K. SHIP expression
also inhibited hormone-stimulated membrane ru¥ing (a con-
sequence of actin rearrangement), p42/44 mitogen-activated
protein kinase (MAPK) phosphorylation and DNA synthesis
[35]. The same group then examined the e¡ect of tumour
suppressor PTEN (phosphatase and tensin homologue deleted
on chromosome 10), a lipid 3-phosphatase [36]. Nakashima et
al. over-expressed PTEN in 3T3-L1 adipocytes and observed a
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decrease in insulin-stimulated GLUT4 translocation, glucose
transport and membrane ru¥ing, which coincided with re-
duced phosphorylation of PKB and p70S6K but normal phos-
phorylation of p42/44 MAPK [36]. Furthermore, inhibition of
endogenous PTEN by microinjection of anti-PTEN antibodies
resulted in increased basal and insulin-stimulated glucose
transport [36].
3.2. E¡ects of ceramide on PKB activation and
glucose transport
Tumour necrosis factor (TNF)-K, a potent cytokine pro-
duced by macrophages, causes a profound reduction in insu-
lin-stimulated glucose transport in skeletal muscle and adipo-
cytes of rats [37]. The molecular mechanism by which TNF-K
induces insulin resistance in these tissues remains unclear, but
a key event in signal transduction pathways initiated by TNF-
K involves the increased turnover of membrane sphingomye-
lin, and the concomitant production of ceramide [38]. Levels
of ceramide are elevated in skeletal muscle of insulin resistant
rats [39]. Ceramide has been shown to impair the hormonal
activation of IRS-1 and PI3K [40^43], although in other stud-
ies it has been reported to act downstream of PI3K and to
target PKB [44^46]. These latter studies have shown that in
adipocytes and muscle cells, ceramide induces a profound in-
hibition in the insulin-induced stimulation of PKB. This ¢nd-
ing raises the possibility that the loss in insulin-stimulated
glucose transport in adipocytes and muscle cells may, at least
in part, be the consequence of reduced PKB activation. Stud-
ies in cultured muscle cells indicate that this diminished acti-
vation of PKB cannot be attributed to a loss in the insulin-
dependent synthesis of 3-phosphoinositides or to defects in
PDK1, but instead is primarily due to the impaired translo-
cation of PKB to the plasma membrane [47]. Expressing a
membrane-targeted form of PKB in both 3T3-L1 adipocytes
[45] and L6 muscle cells [47] circumvents the inhibition ex-
erted by ceramide on insulin-stimulated glucose transport.
These studies provide strong evidence that PKB activation is
likely to be a key step in the signalling sequelae that promote
an increase in glucose transport. It is unclear whether the 3-
phosphoinositide-dependent translocation of PKB, which can
be disrupted by ceramide, involves other accessory factors, or
simply re£ects a greater proportion of PKB binding at the
membrane in the presence of increased 3-phosphoinositide
concentrations.
3.3. Regulation of PKB activation and glucose transport by
oxidant and osmotic stresses
Increased oxidant levels are a characteristic feature of in-
sulin resistant states, and may be important in the progression
of diseases such as diabetes mellitus. Evidence exists in the
literature showing that acute treatment of cells with hydrogen
peroxide (H2O2) activates PKB in a PI3K-dependent manner
[48,49]. However, under these circumstances glucose transport
is not activated by H2O2 [49]. The reason for this may be the
parallel activation of the stress-activated p38 MAPK pathway
by H2O2, which is thought to arrest insulin signalling at a
point downstream of PKB [49]. Preventing the activation of
this stress signalling pathway, using SB 203580, enables H2O2
to exert full insulin-like e¡ects on glucose transport, probably
through its ability to activate PKB [49]. However, it is note-
worthy that prolonged exposure of cells to high levels of ox-
idants impairs early insulin signalling events, resulting in a
substantial loss in PKB activation that correlates with reduced
insulin-mediated translocation of GLUT4 [50,51]. In either
Fig. 1. Proposed model outlining the role played by PKB in the hormonal regulation of glucose metabolism. Insulin promotes the activation of
PKB in a PI3K-dependent fashion, resulting in the phosphorylation and inactivation of GSK3 and concomitant activation of glycogen syn-
thase. Activated PKB may also associate with GLUT4-containing vesicles, promoting their translocation to the plasma membrane leading to a
stimulation of glucose transport.
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case, the e¡ects of acute or chronic H2O2 treatment on PKB
yield results consistent with the idea that this kinase partic-
ipates in the regulation of glucose transport.
Chen and colleagues have examined the in£uence of hyper-
osmotic shock on insulin signalling in 3T3-L1 adipocytes [52].
In this study, Pessin’s group observed that osmotic shock was
e¡ective in inhibiting insulin-stimulated responses including
glucose transport and GLUT4 translocation. They found
that the addition of sorbitol had no e¡ect on early insulin
signalling events including PI3K activation, but observed an
inhibition of PKB phosphorylation and downstream p70S6K
activation, which was attributable to a PP2A-type phospha-
tase activity [52]. The inhibition of insulin responses by hyper-
osmotic shock at the level of PKB is entirely consistent with
the perceived role of the kinase as a key regulator of glucose
transport, and may re£ect the chronic in vivo e¡ects of hyper-
glycaemia.
3.4. The actin cytoskeleton, PKB activation and glucose
transport ^ possible inter-relationships
There is growing recognition of the idea that the actin cy-
toskeleton may act as a sca¡old for the binding of molecules
involved in insulin signalling, and that this may be important
both for remodelling of the actin network and for signal prop-
agation to key end-point responses [25,53]. Indeed, disassem-
bly of the actin network, using cytochalasin D, has been
shown to prevent activation of glucose transport by insulin
[53]. Recent work from our laboratory indicates that this loss
in glucose transport stimulation may be the consequence of a
substantial reduction in insulin’s ability to stimulate PKB [4].
Translocation analyses of tagged PH domains, which act as
sensitive and selective probes to detect the membrane gener-
ation of 3-phosphoinositides [54], indicate that the reduced
activation of PKB stems from a loss in the stimulus-mediated
synthesis of these phospholipids. The impaired production of
3-phosphoinositides occurs despite normal catalytic activation
of PI3K in vitro, indicating that an intact cytoskeleton may be
necessary for placing PI3K in close proximity to its lipid sub-
strates. Reformation of the actin network reinstates the ca-
pacity of the cells to (i) generate 3-phosphoinositides,
(ii) phosphorylate PKB and GSK3, and (iii) stimulate glucose
transport, in response to insulin [4,55].
3.5. Does impaired PKB activation have a role to play in the
pathogenesis of insulin resistance?
If PKB signalling is an important determinant of glucose
metabolism in vivo then one might expect that its activation
would be dysfunctional under circumstances when utilisation
of glucose in tissues such as skeletal muscle and fat is signi¢-
cantly impaired. If this is so, defects in PKB activation may
play an important role in the pathogenesis and progression of
insulin resistance. However, a number of recent studies per-
formed in rats, mice and humans have been unable to provide
any clarity on this issue. For example, PKB activation by
insulin has been shown to be impaired signi¢cantly in adipo-
cytes isolated from diabetic rats [56], mice [57] and from type
II diabetic humans, as well as in skeletal muscle from hyper-
glycaemic rats [58^61]. In contrast, data also exist showing
that the insulin-mediated phosphorylation of PKB is not al-
tered signi¢cantly in fat cells of diabetic rats [62] or in skeletal
muscle from humans with type II diabetes [63,64]. Moreover,
analysis of genomic DNA or skeletal muscle-derived cDNAs
from NIDDM patients did not result in the identi¢cation of
any mutations in PKBK or PKBL [65]. The reasons for the
above discrepancies are unclear, but may, in part, be attrib-
utable to the involvement of certain PI3K-independent signal-
ling mechanisms that are known to regulate PKB [66,67].
Thus, it is not possible at present to assess what contribution,
if any, defects in PKB activation may make toward the patho-
genesis of insulin resistance in vivo.
4. Conclusions and future directions
Our understanding of the molecular mechanisms by which
insulin modulates glucose transport into muscle and fat cells
has progressed rapidly in recent years. Since the discovery of
PKB it has become increasingly clear that this kinase per-
forms a key intermediary role in the hormonal regulation of
glucose metabolism. However, there are many questions that
remain unanswered. One priority is to establish the identity of
the putative PDK2 kinase, and another to elucidate in greater
detail the mechanism by which PKB is recruited to the mem-
brane for activation. In addition, more knowledge is required
about the identity of downstream substrates and e¡ectors of
PKB. In this regard, we still know very little about the man-
ner in which activated PKB e¡ects the translocation of
GLUT4 vesicles to the plasma membrane, and how other
signalling molecules, such as PKCj/V, may be involved in
regulating this process. Although it seems likely that impair-
ment in PKB function is a feature of insulin resistance, it
remains to be established whether this represents a causal
factor or is merely a consequence of some other molecular
defect. In addition, it is an intriguing possibility that arti¢cial
restoration of the downstream e¡ects of PKB activation may
provide bene¢cial e¡ects during insulin resistant states. By
addressing some of the above issues, we should gain further
important insights into the fundamental physiological process
of glucose homeostasis, and develop better strategies to com-
bat its pathological dysfunction.
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